Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial
By
Chengshui Chen
Xinyu Liang
Zheng Peng
Yan Zou
Huijuan He
Xiaoyan Zhang
Yi He
Shixiu Wu
May 1, 2026
Clinical Scorecard: Evaluation of Upadacitinib for Dermatitis Associated with Immune Checkpoint Inhibitors: Findings from a Nonrandomized Clinical Study
At a Glance
Category Detail
Condition Immune checkpoint inhibitor-related dermatitis Key Mechanisms Selective Janus kinase (JAK) 1 inhibition in the JAK-STAT pathway Target Population Patients with grades 3-4 ICI-related dermatitis Care Setting Single-center, open-label, nonrandomized clinical trial
Key Highlights
100% resolution rate of dermatitis by day 28 Significant improvement in pruritus within 1 day No serious adverse events related to upadacitinib 93.9% of patients continued ICI treatment as scheduled Rapid rash relief observed within 3 to 5 days in 51.5% of patients Guideline-Based Recommendations
Diagnosis
Diagnosis of grades 3-4 ICI-related dermatitis Management
Oral upadacitinib (15 mg/d) for 28 days without concomitant glucocorticoids or immunosuppressants Monitoring & Follow-up
Monitor for adverse events, particularly creatine kinase elevation Risks
Potential for severe infection and gastrointestinal bleeding with corticosteroids Patient & Prescribing Data
Treatment-naive patients with severe ICI-related dermatitis
Upadacitinib shows rapid efficacy and fewer adverse events compared to traditional corticosteroid treatment
Clinical Best Practices
Consider upadacitinib as a therapeutic option for ICI-related dermatitis Monitor patients closely for adverse events during treatment Encourage continuation of ICI therapy if dermatitis resolves Related Resources & Content
